![]() ![]() SRL Diagnostics is the second largest diagnostic company in India in terms of revenue but we are the number one in terms of network, we have more than 420 plus laboratories cross the country catering to over 600+ cities. So we also looked at how we can innovate in terms of how the patients get the reports and we have collaborated with National Digital Health Mission in terms of setting up the digital health cards and being a national health information provider, we have registered with NDHM as a national health information provider and this helps us to be a part of the core process of digital health platforms that will come up in India. Getting specialised skilled pathologists across all locations is difficult and having this kind of a network helps us to use the capabilities across the board. So these initiatives along with total lab automations and the digital pathology set ups that we have and digital pathology networks that we have developed in Bangalore, in Goregaon and in Gurgaon, this helps us to have a better focus on you know how we actually use the manpower across different locations. ![]() We have further extended and this year we are working with Microsoft on breast cancer to develop AI based algorithms. So what we have done is in 2019, we had done a tie-up with Microsoft to work on artificial intelligence to develop algorithms for cervical cancer detection through the liquid based cytology model. We have also started the use of artificial intelligence and machine learning networks to understand better the pathology and use these applications for digital pathology. ![]() These initiatives coupled with the backend integration of various facilities that we have in terms of how we transform digitally the backend of the lab. But we also found that collecting the reports, booking an appointment and accessing the reports and booking appointments for coming to the lab was also a very critical aspect and people wanted to do it digitally, we actually improved our website and our digital access platforms like apps where people could come and book their tests as well as check out their reports and book appointments for home visits. So these initiatives were taken mainly to help the COVID 19 patients in giving the samples. We also created drive through centers at many of the cities where people can drive in with their cars and then from the car itself, they can give the sample and leave, thereby having minimal exposure to the environment. With this in mind, what we did was, you know, we had ramped up our home collection facilities and we started off with adding more phlebotomists who can go and do these tests at home. So these changes are also very critical and digital transformation has been fast tracked because of the pandemic.ĬOVID 19: SRL Diagnostics – Initiatives and Innovationsīecause of the pandemic, we have started a lot of new initiatives, especially in terms of handling COVID 19 samples, so what we found is that the patients were not able to travel to different places because of the lockdown during the first wave of the pandemic and then later as well there was a fear of transmission of COVID and people wanted to get tested, not only from their homes but in their confined environments rather than coming out and getting themselves exposed. So the consumers, since they are not able to come physically to the various collection centers or facilities of diagnostics, they have chosen to look at digital options, so they look for home collection, they look for, you know apps and web based applications that they can use to book home visits, to view their reports, to book any appointments. We also have to note that this pandemic has put up challenges in terms of how the consumer looks at it. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |